Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Quazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GHSR | Q92847 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quazepam SCHEMBL29534458 | 1.00 | OPRK1 (0.58) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL21647120 | 0.99 | OPRK1 (0.57) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL9757526 | 0.90 | OPRK1 (0.59) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL9848810 | 0.87 | OPRK1 (0.41) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL5379874 | 0.87 | OPRK1 (0.77) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| SCHEMBL13531318 | 0.87 | OPRK1 (0.62) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL3177949 | 0.85 | OPRK1 (0.45) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL1181404 | 0.85 | OPRK1 (0.66) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL6524231 | 0.82 | LMNA (0.56) | OPRK1NR1I2ADORA3OPRM1DRD3 | |
| Quazepam SCHEMBL28142863 | 0.80 | PTAFR (0.61) | OPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8905 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260063626-A1 | COMPARTMENTAL ANALYSIS OF EXTRACORPOREAL LIVER PERFUSION SYSTEMS | HEPQUANT LLC (US) | 2026-03-05 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | claimed |
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250281451-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. | 2025-09-11 | — | — | US | claimed |
| US-12396981-B2 | Methods of using DMT | SHULMAN WILLIAM (US) | 2025-08-26 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| WO-2025126159-A1 | A METHOD FOR TREATING A NEUROLOGICAL DISEASE IN A RECREATIONAL DRUG USER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | WO | claimed |
| US-5858004-A | Head projections on shielded butterfly needle assemblies | SHIELDS JACK W (US) | 1999-01-12 | — | — | US | claimed |
| WO-1997041879-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| CN-1151893-A | Combination antiemetic therapy using NK-1 receptor antagonists | PFIZER (US) | 1997-06-18 | — | — | CN | claimed |
| EP-0769300-A2 | Antiemetic composition containing an NK-1 receptor antagonists | PFIZER INC. (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0579435-A1 | Cyclodextrin complexation | CYCLOPS h.f. (IS) | 1994-01-19 | — | — | EP | claimed |
| US-5248678-A | Administering adenosine receptor antagonist and a GABA antagonist | FRACTAL LABORATORIES, INC. (US) | 1993-09-28 | — | — | US | claimed |
| EP-0428272-A2 | Trifluorobenzodiazepine compounds for use in therapy by intraoral administration | Ellinwood, Everett Hews (US) | 1991-05-22 | — | — | EP | claimed |
| US-4721709-A | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions | PYARE SETH (CH) | 1988-01-26 | — | — | US | claimed |
| US-4649939-A | Mid-hind foot stabilizer | NIKE, INC. | 1987-03-17 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |